Share Price and Basic Stock Data
Last Updated: November 5, 2025, 5:25 pm
| PEG Ratio | 1.37 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Solara Active Pharma Sciences Ltd, operating in the pharmaceuticals sector, reported a current market price of ₹588 and a market capitalization of ₹2,626 Cr. The company has experienced fluctuating sales over recent quarters, with the highest quarterly sales recorded at ₹425 Cr in September 2023. In the trailing twelve months (TTM), total sales stood at ₹1,239 Cr, reflecting a decline from ₹1,289 Cr in FY 2024 and ₹1,444 Cr in FY 2023. The sales trajectory indicates challenges, particularly with a significant drop in sales to ₹212 Cr in December 2023, followed by recovery to ₹299 Cr in March 2024. Overall, the revenue performance underscores a need for strategic adjustments to stabilize growth amid industry competition.
Profitability and Efficiency Metrics
Profitability metrics reveal a complex financial landscape for Solara Active Pharma Sciences. The reported operating profit margin (OPM) stood at 18%, but the quarterly performance showed volatility, with an OPM of -76% in December 2023, indicating severe operational inefficiencies. The company recorded a net profit of ₹25 Cr, translating to a P/E ratio of 107, which is notably high compared to typical industry standards. The return on equity (ROE) was just 0.05%, while return on capital employed (ROCE) was at 6.01%. These figures reflect challenges in generating value for shareholders, as seen in the declining net profit margins, which fell to 0.04% in March 2025 from more robust levels in prior years.
Balance Sheet Strength and Financial Ratios
Solara’s balance sheet shows a mixed picture of financial health. Total borrowings amounted to ₹796 Cr against reserves of ₹1,054 Cr, suggesting a manageable debt level with a debt-to-equity ratio of 0.70. The interest coverage ratio (ICR) stood at 1.87, indicating that the company can cover its interest obligations, albeit with limited buffer. The current ratio of 0.77 highlights liquidity concerns, as it falls below the ideal benchmark of 1. This may signal challenges in meeting short-term liabilities. The book value per share has seen a decline, reported at ₹271.86 in FY 2025, down from ₹417.35 in FY 2023, indicating potential erosion of net worth, which could affect investor sentiment.
Shareholding Pattern and Investor Confidence
Investor confidence in Solara is reflected in its shareholding pattern, where promoters hold 42.01% of the company, indicating strong management control. However, foreign institutional investors (FIIs) have reduced their stake to 14.25%, down from a peak of 19.30% in March 2023, suggesting a cautious stance among international investors. Domestic institutional investors (DIIs) hold 2.62%, showing limited institutional interest. The public shareholding stands at 41.10%, indicating a diverse ownership base among retail investors. The number of shareholders has decreased to 74,334, which may reflect concerns over the company’s recent performance and profitability metrics.
Outlook, Risks, and Final Insight
The outlook for Solara Active Pharma Sciences involves navigating both opportunities and risks. Strengths include a solid market presence in the pharmaceuticals sector and a manageable debt profile, which can support future growth initiatives. However, significant risks include operational inefficiencies, as evidenced by fluctuating profit margins, and declining sales trends, which could hinder growth prospects. Additionally, liquidity challenges, indicated by the current ratio, raise concerns about short-term financial stability. Moving forward, the company must focus on operational improvements and strategic investments to enhance profitability and restore investor confidence, ensuring a sustainable path for growth in a competitive environment.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Solara Active Pharma Sciences Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 142 Cr. | 113 | 247/84.3 | 32.4 | 46.7 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.63 Cr. | 1.90 | 4.33/1.90 | 0.57 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 5,019 Cr. | 461 | 479/192 | 113 | 22.8 | 0.15 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 34.0 Cr. | 45.9 | 92.2/37.2 | 8.73 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 35.8 Cr. | 24.4 | 29.1/17.0 | 37.3 | 6.83 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,833.71 Cr | 1,197.00 | 54.56 | 196.97 | 0.33% | 16.24% | 14.95% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 330 | 338 | 395 | 381 | 352 | 425 | 212 | 299 | 363 | 347 | 300 | 273 | 319 |
| Expenses | 318 | 311 | 350 | 332 | 333 | 388 | 374 | 290 | 322 | 286 | 243 | 228 | 262 |
| Operating Profit | 13 | 28 | 45 | 49 | 19 | 38 | -162 | 10 | 42 | 61 | 58 | 45 | 57 |
| OPM % | 4% | 8% | 11% | 13% | 5% | 9% | -76% | 3% | 12% | 18% | 19% | 17% | 18% |
| Other Income | 7 | 4 | 7 | 5 | 2 | -4 | -62 | -120 | 1 | 0 | 1 | 6 | 1 |
| Interest | 22 | 22 | 24 | 22 | 25 | 24 | 25 | 31 | 31 | 28 | 27 | 29 | 24 |
| Depreciation | 28 | 29 | 28 | 26 | 26 | 26 | 26 | 25 | 25 | 25 | 25 | 24 | 24 |
| Profit before tax | -31 | -19 | 1 | 5 | -29 | -17 | -275 | -167 | -13 | 8 | 8 | -2 | 11 |
| Tax % | -47% | -48% | 22% | 25% | -35% | 0% | 0% | 53% | 0% | 0% | 0% | 0% | 0% |
| Net Profit | -16 | -10 | 0 | 4 | -19 | -17 | -275 | -255 | -13 | 8 | 8 | -2 | 11 |
| EPS in Rs | -3.42 | -2.08 | 0.09 | 0.79 | -4.07 | -3.58 | -57.36 | -53.20 | -3.74 | 2.22 | 2.24 | -0.58 | 2.91 |
Last Updated: August 1, 2025, 11:20 am
Below is a detailed analysis of the quarterly data for Solara Active Pharma Sciences Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 319.00 Cr.. The value appears strong and on an upward trend. It has increased from 273.00 Cr. (Mar 2025) to 319.00 Cr., marking an increase of 46.00 Cr..
- For Expenses, as of Jun 2025, the value is 262.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 228.00 Cr. (Mar 2025) to 262.00 Cr., marking an increase of 34.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 57.00 Cr.. The value appears strong and on an upward trend. It has increased from 45.00 Cr. (Mar 2025) to 57.00 Cr., marking an increase of 12.00 Cr..
- For OPM %, as of Jun 2025, the value is 18.00%. The value appears strong and on an upward trend. It has increased from 17.00% (Mar 2025) to 18.00%, marking an increase of 1.00%.
- For Other Income, as of Jun 2025, the value is 1.00 Cr.. The value appears to be declining and may need further review. It has decreased from 6.00 Cr. (Mar 2025) to 1.00 Cr., marking a decrease of 5.00 Cr..
- For Interest, as of Jun 2025, the value is 24.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 29.00 Cr. (Mar 2025) to 24.00 Cr., marking a decrease of 5.00 Cr..
- For Depreciation, as of Jun 2025, the value is 24.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 24.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 11.00 Cr.. The value appears strong and on an upward trend. It has increased from -2.00 Cr. (Mar 2025) to 11.00 Cr., marking an increase of 13.00 Cr..
- For Tax %, as of Jun 2025, the value is 0.00%. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00%.
- For Net Profit, as of Jun 2025, the value is 11.00 Cr.. The value appears strong and on an upward trend. It has increased from -2.00 Cr. (Mar 2025) to 11.00 Cr., marking an increase of 13.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 2.91. The value appears strong and on an upward trend. It has increased from -0.58 (Mar 2025) to 2.91, marking an increase of 3.49.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 4:24 am
| Metric | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 521 | 1,387 | 1,322 | 1,617 | 1,268 | 1,444 | 1,289 | 1,284 | 1,239 |
| Expenses | 464 | 1,174 | 1,062 | 1,231 | 1,188 | 1,309 | 1,384 | 1,077 | 1,018 |
| Operating Profit | 57 | 213 | 260 | 386 | 81 | 134 | -95 | 206 | 221 |
| OPM % | 11% | 15% | 20% | 24% | 6% | 9% | -7% | 16% | 18% |
| Other Income | 2 | 12 | 27 | 29 | 16 | 22 | -185 | 8 | 9 |
| Interest | 25 | 82 | 78 | 84 | 75 | 90 | 105 | 115 | 108 |
| Depreciation | 34 | 83 | 94 | 109 | 112 | 111 | 103 | 99 | 98 |
| Profit before tax | 0 | 60 | 115 | 222 | -91 | -45 | -488 | 1 | 25 |
| Tax % | -70% | 1% | 0% | 0% | -36% | -50% | 16% | 0% | |
| Net Profit | 0 | 59 | 115 | 221 | -58 | -22 | -567 | 1 | 25 |
| EPS in Rs | 17.30 | 32.01 | 46.22 | -12.11 | -4.62 | -118.21 | 0.15 | 6.79 | |
| Dividend Payout % | 0% | 22% | 5% | 11% | 0% | -49% | 0% | 0% |
YoY Net Profit Growth
| Year | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 94.92% | 92.17% | -126.24% | 62.07% | -2477.27% | 100.18% |
| Change in YoY Net Profit Growth (%) | 0.00% | -2.74% | -218.42% | 188.31% | -2539.34% | 2577.45% |
Solara Active Pharma Sciences Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 6 years from 2019-2020 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -1% |
| 3 Years: | 0% |
| TTM: | -5% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -66% |
| 3 Years: | 26% |
| TTM: | 106% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | -5% |
| 3 Years: | 18% |
| 1 Year: | -9% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | -4% |
| 3 Years: | -11% |
| Last Year: | 0% |
Last Updated: September 5, 2025, 1:31 pm
Balance Sheet
Last Updated: September 10, 2025, 2:32 pm
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 25 | 26 | 27 | 36 | 36 | 36 | 36 | 40 |
| Reserves | 739 | 930 | 1,059 | 1,553 | 1,489 | 1,464 | 898 | 1,054 |
| Borrowings | 633 | 538 | 722 | 621 | 1,037 | 1,013 | 1,012 | 796 |
| Other Liabilities | 425 | 466 | 346 | 404 | 383 | 386 | 406 | 342 |
| Total Liabilities | 1,821 | 1,960 | 2,153 | 2,614 | 2,945 | 2,899 | 2,351 | 2,232 |
| Fixed Assets | 1,086 | 1,218 | 1,397 | 1,382 | 1,356 | 1,364 | 1,268 | 1,193 |
| CWIP | 71 | 40 | 40 | 88 | 239 | 238 | 256 | 280 |
| Investments | 1 | 0 | 0 | 0 | 0 | 2 | 2 | 2 |
| Other Assets | 663 | 701 | 716 | 1,144 | 1,350 | 1,295 | 825 | 757 |
| Total Assets | 1,821 | 1,960 | 2,153 | 2,614 | 2,945 | 2,899 | 2,351 | 2,232 |
Below is a detailed analysis of the balance sheet data for Solara Active Pharma Sciences Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 40.00 Cr.. The value appears strong and on an upward trend. It has increased from 36.00 Cr. (Mar 2024) to 40.00 Cr., marking an increase of 4.00 Cr..
- For Reserves, as of Mar 2025, the value is 1,054.00 Cr.. The value appears strong and on an upward trend. It has increased from 898.00 Cr. (Mar 2024) to 1,054.00 Cr., marking an increase of 156.00 Cr..
- For Borrowings, as of Mar 2025, the value is 796.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 1,012.00 Cr. (Mar 2024) to 796.00 Cr., marking a decrease of 216.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 342.00 Cr.. The value appears to be improving (decreasing). It has decreased from 406.00 Cr. (Mar 2024) to 342.00 Cr., marking a decrease of 64.00 Cr..
- For Total Liabilities, as of Mar 2025, the value is 2,232.00 Cr.. The value appears to be improving (decreasing). It has decreased from 2,351.00 Cr. (Mar 2024) to 2,232.00 Cr., marking a decrease of 119.00 Cr..
- For Fixed Assets, as of Mar 2025, the value is 1,193.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,268.00 Cr. (Mar 2024) to 1,193.00 Cr., marking a decrease of 75.00 Cr..
- For CWIP, as of Mar 2025, the value is 280.00 Cr.. The value appears strong and on an upward trend. It has increased from 256.00 Cr. (Mar 2024) to 280.00 Cr., marking an increase of 24.00 Cr..
- For Investments, as of Mar 2025, the value is 2.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 2.00 Cr..
- For Other Assets, as of Mar 2025, the value is 757.00 Cr.. The value appears to be declining and may need further review. It has decreased from 825.00 Cr. (Mar 2024) to 757.00 Cr., marking a decrease of 68.00 Cr..
- For Total Assets, as of Mar 2025, the value is 2,232.00 Cr.. The value appears to be declining and may need further review. It has decreased from 2,351.00 Cr. (Mar 2024) to 2,232.00 Cr., marking a decrease of 119.00 Cr..
Notably, the Reserves (1,054.00 Cr.) exceed the Borrowings (796.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -576.00 | -325.00 | -462.00 | -235.00 | 80.00 | 133.00 | -96.00 | -590.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 184 | 76 | 63 | 109 | 141 | 136 | 99 | 93 |
| Inventory Days | 252 | 111 | 170 | 149 | 321 | 258 | 163 | 185 |
| Days Payable | 420 | 127 | 132 | 156 | 154 | 142 | 142 | 145 |
| Cash Conversion Cycle | 16 | 60 | 101 | 102 | 308 | 252 | 120 | 133 |
| Working Capital Days | -124 | -22 | -32 | 16 | 37 | 20 | -128 | -62 |
| ROCE % | 10% | 12% | 15% | -0% | 2% | -9% | 6% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Aditya Birla Sun Life Flexi Cap Fund | 420,000 | 0.12 | 26.96 | 420,000 | 2025-04-22 17:25:20 | 0% |
| Aditya Birla Sun Life Manufacturing Equity Fund | 146,107 | 0.88 | 9.38 | 65,000 | 2025-08-29 00:02:49 | 124.78% |
| Motilal Oswal BSE Healthcare ETF | 729 | 0.15 | 0.05 | N/A | N/A | N/A |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 0.14 | -157.62 | -6.16 | -16.18 | 69.00 |
| Diluted EPS (Rs.) | 0.14 | -157.62 | -6.16 | -16.18 | 64.53 |
| Cash EPS (Rs.) | 24.79 | -128.79 | 24.70 | 15.01 | 91.87 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 271.86 | 260.16 | 417.35 | 424.22 | 443.42 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 271.86 | 260.16 | 417.35 | 424.22 | 443.42 |
| Revenue From Operations / Share (Rs.) | 318.95 | 358.03 | 401.06 | 352.32 | 450.13 |
| PBDIT / Share (Rs.) | 53.32 | -24.95 | 43.45 | 27.77 | 115.43 |
| PBIT / Share (Rs.) | 28.66 | -53.65 | 12.57 | -3.42 | 85.18 |
| PBT / Share (Rs.) | 0.13 | -135.67 | -12.45 | -25.31 | 61.66 |
| Net Profit / Share (Rs.) | 0.13 | -157.49 | -6.18 | -16.19 | 61.62 |
| NP After MI And SOA / Share (Rs.) | 0.13 | -157.61 | -6.16 | -16.15 | 61.64 |
| PBDIT Margin (%) | 16.71 | -6.96 | 10.83 | 7.88 | 25.64 |
| PBIT Margin (%) | 8.98 | -14.98 | 3.13 | -0.97 | 18.92 |
| PBT Margin (%) | 0.04 | -37.89 | -3.10 | -7.18 | 13.69 |
| Net Profit Margin (%) | 0.04 | -43.98 | -1.54 | -4.59 | 13.68 |
| NP After MI And SOA Margin (%) | 0.04 | -44.02 | -1.53 | -4.58 | 13.69 |
| Return on Networth / Equity (%) | 0.04 | -60.75 | -1.47 | -3.81 | 13.93 |
| Return on Capital Employeed (%) | 8.95 | -17.42 | 2.51 | -0.65 | 16.76 |
| Return On Assets (%) | 0.02 | -24.13 | -0.76 | -1.96 | 8.47 |
| Long Term Debt / Equity (X) | 0.10 | 0.11 | 0.15 | 0.18 | 0.09 |
| Total Debt / Equity (X) | 0.70 | 1.07 | 0.66 | 0.67 | 0.32 |
| Asset Turnover Ratio (%) | 0.56 | 0.49 | 0.49 | 0.45 | 0.67 |
| Current Ratio (X) | 0.77 | 0.64 | 1.08 | 1.16 | 1.34 |
| Quick Ratio (X) | 0.43 | 0.35 | 0.57 | 0.61 | 0.96 |
| Inventory Turnover Ratio (X) | 1.72 | 1.66 | 1.37 | 1.97 | 2.38 |
| Dividend Payout Ratio (NP) (%) | 0.00 | 0.00 | 0.00 | -18.53 | 8.90 |
| Dividend Payout Ratio (CP) (%) | 0.00 | 0.00 | 0.00 | 19.90 | 5.97 |
| Earning Retention Ratio (%) | 0.00 | 0.00 | 0.00 | 118.53 | 91.10 |
| Cash Earning Retention Ratio (%) | 0.00 | 0.00 | 0.00 | 80.10 | 94.03 |
| Interest Coverage Ratio (X) | 1.87 | -0.85 | 1.74 | 1.33 | 4.91 |
| Interest Coverage Ratio (Post Tax) (X) | 1.00 | -2.58 | 0.75 | 0.27 | 3.62 |
| Enterprise Value (Cr.) | 3238.30 | 2334.27 | 2176.74 | 3374.17 | 5329.56 |
| EV / Net Operating Revenue (X) | 2.21 | 1.81 | 1.51 | 2.66 | 3.30 |
| EV / EBITDA (X) | 13.23 | -25.99 | 13.92 | 33.74 | 12.85 |
| MarketCap / Net Operating Revenue (X) | 1.61 | 1.04 | 0.81 | 1.89 | 3.10 |
| Retention Ratios (%) | 0.00 | 0.00 | 0.00 | 118.53 | 91.09 |
| Price / BV (X) | 1.89 | 1.44 | 0.78 | 1.57 | 3.15 |
| Price / Net Operating Revenue (X) | 1.61 | 1.04 | 0.81 | 1.89 | 3.10 |
| EarningsYield | 0.00 | -0.42 | -0.01 | -0.02 | 0.04 |
After reviewing the key financial ratios for Solara Active Pharma Sciences Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 0.14. This value is below the healthy minimum of 5. It has increased from -157.62 (Mar 24) to 0.14, marking an increase of 157.76.
- For Diluted EPS (Rs.), as of Mar 25, the value is 0.14. This value is below the healthy minimum of 5. It has increased from -157.62 (Mar 24) to 0.14, marking an increase of 157.76.
- For Cash EPS (Rs.), as of Mar 25, the value is 24.79. This value is within the healthy range. It has increased from -128.79 (Mar 24) to 24.79, marking an increase of 153.58.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 271.86. It has increased from 260.16 (Mar 24) to 271.86, marking an increase of 11.70.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 271.86. It has increased from 260.16 (Mar 24) to 271.86, marking an increase of 11.70.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 318.95. It has decreased from 358.03 (Mar 24) to 318.95, marking a decrease of 39.08.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 53.32. This value is within the healthy range. It has increased from -24.95 (Mar 24) to 53.32, marking an increase of 78.27.
- For PBIT / Share (Rs.), as of Mar 25, the value is 28.66. This value is within the healthy range. It has increased from -53.65 (Mar 24) to 28.66, marking an increase of 82.31.
- For PBT / Share (Rs.), as of Mar 25, the value is 0.13. This value is within the healthy range. It has increased from -135.67 (Mar 24) to 0.13, marking an increase of 135.80.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 0.13. This value is below the healthy minimum of 2. It has increased from -157.49 (Mar 24) to 0.13, marking an increase of 157.62.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 0.13. This value is below the healthy minimum of 2. It has increased from -157.61 (Mar 24) to 0.13, marking an increase of 157.74.
- For PBDIT Margin (%), as of Mar 25, the value is 16.71. This value is within the healthy range. It has increased from -6.96 (Mar 24) to 16.71, marking an increase of 23.67.
- For PBIT Margin (%), as of Mar 25, the value is 8.98. This value is below the healthy minimum of 10. It has increased from -14.98 (Mar 24) to 8.98, marking an increase of 23.96.
- For PBT Margin (%), as of Mar 25, the value is 0.04. This value is below the healthy minimum of 10. It has increased from -37.89 (Mar 24) to 0.04, marking an increase of 37.93.
- For Net Profit Margin (%), as of Mar 25, the value is 0.04. This value is below the healthy minimum of 5. It has increased from -43.98 (Mar 24) to 0.04, marking an increase of 44.02.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 0.04. This value is below the healthy minimum of 8. It has increased from -44.02 (Mar 24) to 0.04, marking an increase of 44.06.
- For Return on Networth / Equity (%), as of Mar 25, the value is 0.04. This value is below the healthy minimum of 15. It has increased from -60.75 (Mar 24) to 0.04, marking an increase of 60.79.
- For Return on Capital Employeed (%), as of Mar 25, the value is 8.95. This value is below the healthy minimum of 10. It has increased from -17.42 (Mar 24) to 8.95, marking an increase of 26.37.
- For Return On Assets (%), as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. It has increased from -24.13 (Mar 24) to 0.02, marking an increase of 24.15.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.10. This value is below the healthy minimum of 0.2. It has decreased from 0.11 (Mar 24) to 0.10, marking a decrease of 0.01.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.70. This value is within the healthy range. It has decreased from 1.07 (Mar 24) to 0.70, marking a decrease of 0.37.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.56. It has increased from 0.49 (Mar 24) to 0.56, marking an increase of 0.07.
- For Current Ratio (X), as of Mar 25, the value is 0.77. This value is below the healthy minimum of 1.5. It has increased from 0.64 (Mar 24) to 0.77, marking an increase of 0.13.
- For Quick Ratio (X), as of Mar 25, the value is 0.43. This value is below the healthy minimum of 1. It has increased from 0.35 (Mar 24) to 0.43, marking an increase of 0.08.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 1.72. This value is below the healthy minimum of 4. It has increased from 1.66 (Mar 24) to 1.72, marking an increase of 0.06.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 1.87. This value is below the healthy minimum of 3. It has increased from -0.85 (Mar 24) to 1.87, marking an increase of 2.72.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 1.00. This value is below the healthy minimum of 3. It has increased from -2.58 (Mar 24) to 1.00, marking an increase of 3.58.
- For Enterprise Value (Cr.), as of Mar 25, the value is 3,238.30. It has increased from 2,334.27 (Mar 24) to 3,238.30, marking an increase of 904.03.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 2.21. This value is within the healthy range. It has increased from 1.81 (Mar 24) to 2.21, marking an increase of 0.40.
- For EV / EBITDA (X), as of Mar 25, the value is 13.23. This value is within the healthy range. It has increased from -25.99 (Mar 24) to 13.23, marking an increase of 39.22.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.61. This value is within the healthy range. It has increased from 1.04 (Mar 24) to 1.61, marking an increase of 0.57.
- For Retention Ratios (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 30. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Price / BV (X), as of Mar 25, the value is 1.89. This value is within the healthy range. It has increased from 1.44 (Mar 24) to 1.89, marking an increase of 0.45.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.61. This value is within the healthy range. It has increased from 1.04 (Mar 24) to 1.61, marking an increase of 0.57.
- For EarningsYield, as of Mar 25, the value is 0.00. This value is below the healthy minimum of 5. It has increased from -0.42 (Mar 24) to 0.00, marking an increase of 0.42.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Solara Active Pharma Sciences Ltd:
- Net Profit Margin: 0.04%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 8.95% (Industry Average ROCE: 16.24%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 0.04% (Industry Average ROE: 14.95%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 1
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.43
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 112 (Industry average Stock P/E: 54.56)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.7
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 0.04%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | �Cyber One�, Unit No. 902, Plot No. 4 & 6, Sector 30A, New Mumbai Maharashtra 400703 | investors@solara.co.in http://www.solara.co.in |
| Management | |
|---|---|
| Name | Position Held |
| Mr. R Ramakrishnan | Chairperson & Independent Director |
| Mr. Sandeep Shashikantha Rao | Managing Director & CEO |
| Mr. Mohan Muthunarayanan | Whole Time Director & COO |
| Mr. Manish Gupta | Non Executive Director |
| Mr. Kartheek Chintalapati Raju | Non Executive Director |
| Mr. Arun Kumar Pillai | Non Executive Director |
| Dr. Kausalya Santhanam | Independent Director |
| Mr. Rajiv Vijay Nabar | Independent Director |
| Mr. Rajendra Kumar Srivastava | Independent Director |
FAQ
What is the intrinsic value of Solara Active Pharma Sciences Ltd?
Solara Active Pharma Sciences Ltd's intrinsic value (as of 05 November 2025) is 13.89 which is 97.75% lower the current market price of 617.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 2,751 Cr. market cap, FY2025-2026 high/low of 886/441, reserves of ₹1,054 Cr, and liabilities of 2,232 Cr.
What is the Market Cap of Solara Active Pharma Sciences Ltd?
The Market Cap of Solara Active Pharma Sciences Ltd is 2,751 Cr..
What is the current Stock Price of Solara Active Pharma Sciences Ltd as on 05 November 2025?
The current stock price of Solara Active Pharma Sciences Ltd as on 05 November 2025 is 617.
What is the High / Low of Solara Active Pharma Sciences Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Solara Active Pharma Sciences Ltd stocks is 886/441.
What is the Stock P/E of Solara Active Pharma Sciences Ltd?
The Stock P/E of Solara Active Pharma Sciences Ltd is 112.
What is the Book Value of Solara Active Pharma Sciences Ltd?
The Book Value of Solara Active Pharma Sciences Ltd is 304.
What is the Dividend Yield of Solara Active Pharma Sciences Ltd?
The Dividend Yield of Solara Active Pharma Sciences Ltd is 0.00 %.
What is the ROCE of Solara Active Pharma Sciences Ltd?
The ROCE of Solara Active Pharma Sciences Ltd is 6.01 %.
What is the ROE of Solara Active Pharma Sciences Ltd?
The ROE of Solara Active Pharma Sciences Ltd is 0.05 %.
What is the Face Value of Solara Active Pharma Sciences Ltd?
The Face Value of Solara Active Pharma Sciences Ltd is 10.0.